ABSTRACT
Background
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder significantly reducing quality of life. Silicolgel, a colloidal silicic acid enterosorbent, acts locally in the gut. This double‐blind, placebo‐controlled trial investigated its safety and efficacy in IBS‐D and IBS‐M, subtypes affecting over 60% of IBS sufferers.
Methods
After 2 weeks of screening, patients were randomized into 4 weeks of treatment, followed by a no‐medication phase to assess return of symptoms. Patients recorded bowel habits, abdominal pain, QoL, and global symptoms using weekly questionnaires and daily diaries. Primary outcome was a ≥ 50 point reduction in IBS Severity Scoring System (IBS SSS).
Results
From 139 adults with ROME IV IBS‐D or IBS‐M, 120 were randomized and all completed screening and treatment phases (silicolgel n = 60, placebo n = 60). After 4 weeks' treatment: 91.67% (ITT) achieved the primary outcome in the silicolgel group versus 20.00% for placebo (relative risk (RR) = 4.58, 95% CI 2.74–7.65, p < 0.001). Mean IBS SSS for silicolgel reduced to 92.75 [62.68], −162.87 versus 257.58 [74.94] +3.17 for the placebo group (U = 210.5, r = 0.76, p < 0.001). Silicolgel also improved bowel habit, abdominal pain, distension, flatulence, and QoL. IBS‐D and IBS‐M patients showed the same improvements. Adverse events were similar in both groups, with no serious events attributable to silicolgel or placebo. Onset of action was rapid; after 2 weeks, 85.0% on silicolgel achieved the primary outcome versus 11.7% on placebo (significant difference).
Conclusion
Silicolgel is safe and effective in IBS‐D and IBS‐M, providing an alternative to the limited treatments currently available.
Keywords: double‐blind, enterosorbent, irritable bowel syndrome, placebo‐controlled study, randomized clinical trial, Rome IV, silicolgel
Current treatments often fall short in managing IBS effectively. Silicolgel, an enterosorbent, reduced IBS and other gastrointestinal symptoms in 90% of IBS patients compared to 20% in those on placebo. Enterosorbents are not currently recommended for IBS; silicolgel is a widely available, affordable option for patients with IBS‐D and IBS‐M.

Summary.
Current treatments for irritable bowel syndrome (IBS) often fall short in managing symptoms effectively, particularly for patients with predominant diarrhea (IBS‐D) and IBS with mixed bowel habits (IBS‐M).
Silicolgel, an enterosorbent, rapidly reduced IBS and other gastrointestinal symptoms in over 90% of IBS patients compared to 20% in those treated with placebo.
Enterosorbents are not currently a recommended treatment for IBS; silicolgel is widely available over the counter and is an affordable treatment option for patients with IBS‐D and IBS‐M.
1. Introduction
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders seen in primary and secondary care [1, 2, 3]. IBS subtypes include those with predominant diarrhea (IBS‐D), those with predominant constipation (IBS‐C), those with mixed bowel habits (IBS‐M), and IBS unclassified (IBS‐U) [1, 4]. Rome Foundation (Rome IV) symptom‐based criteria are used in the diagnosis of IBS [4]. A large multinational study reported a global IBS prevalence of 4.1% with the following prevalence of subtypes: IBS‐D 28.7%, IBS‐M 32.4%, IBS‐C 32.4%, and IBS‐U 6.5% [5].
Common IBS symptoms include abdominal pain, altered bowel habits, and abdominal distention/bloating. IBS is associated with comorbidities such as fibromyalgia, chronic fatigue, GI disorders (reflux and dyspepsia), and psychiatric disorders (depression and anxiety) [6, 7, 8, 9, 10, 11, 12]. IBS can greatly impact quality of life (QoL), social functioning, and the ability to work, particularly for patients with IBS‐D and IBS‐M [13, 14, 15, 16].
The economic burden of IBS is considerable, with estimated annual direct healthcare costs of £1.3 billion in the UK, while in Italy the projected costs are €8 billion [17, 18].
Management of IBS is challenging because of its individual and variable nature. Recent IBS treatment guidelines [1, 19] recommend dietary advice and regular exercise. Current IBS therapies include psychological interventions, dietary control, probiotics, and pharmacological drugs which target the most common symptoms. Patients with IBS often use multiple medications and a 2016 survey reported 62% of patients with IBS using two or more medicines regularly [20]. Despite the prevalence of this debilitating condition, there is a lack of effective treatment. In this 2016 survey, only 21% of patients felt confident that their IBS symptoms were under control, and 34% felt that none of their symptoms were under control [20].
Enterosorbents, such as dioctahedral smectite and silicic acid, traditionally used for adsorption of poisons, have shown promise as non‐pharmacological options for IBS management [21, 22, 23, 24, 25]. These substances are categorized as medical devices as their activity results from a physical effect. Although their exact mechanism of action is not fully understood, it is considered to be related to their ability to bind to gut‐irritant molecules (e.g., reactive enterotoxins, pathogens, and bile acids) and a potential muco‐protective effect [21, 22, 23, 26, 27, 28, 29, 30, 31, 32]. Recent clinical trials investigating enterosorbents as IBS treatments have demonstrated significant improvements in IBS symptoms compared with placebo [21, 22, 23].
Silicolgel (silicolgel produced by Silicol GmbH, Germany) is an established medical device in the form of an oral gel containing colloidal silicic acid. Approved for relief of GI disorders, including IBS, silicolgel has been marketed in the UK and European markets for over a decade [33]. An open‐label, post‐marketing study published in 2023 demonstrated the safety and efficacy of silicolgel in a real‐world setting, providing the basis for further investigation [34]. Building on these findings, this clinical trial aims to evaluate the efficacy, safety, and tolerability of silicolgel in patients with IBS‐D and IBS‐M.
2. Methods
2.1. Trial Design
A randomized, double‐blind, placebo‐controlled, multicenter study to assess the efficacy, tolerability, and safety of silicolgel (Filtrum gastro gel in Ukraine) in the treatment of adults with IBS‐D and IBS‐M. Patients with IBS‐C were not included in this particular trial (see trial design in Figure 1).
FIGURE 1.

Study design showing details of screening, treatment, and observation phase. IBS, irritable bowel syndrome; IBS SSS, irritable bowel syndrome severity scoring.
The study was conducted in Ukraine and managed by the Clinical Research Organization (C.R.O.) Verum (https://www.verum.de/en). The incidence of IBS in Ukraine was reported as similar to other European countries, and this contributed to determining an adequate sample size for the study.
Due to the classification status of silicolgel in Ukraine, this trial was ineligible for pre‐registration.
Patients were recruited as outpatients via IBS clinics in four regional health centers in Chernivtsi, Kyiv, Kharkiv, and Vinnytsia.
The study consisted of the following:
- Visit 1 In‐Clinic: Assessment for eligibility, including patient demographics, disease history, pregnancy test, biochemical health checks, and initial symptom data. Full briefing, training for weekly IBS SSS questionnaires (Francis et al. [35]), Daily Diaries, and use of Bristol Stool Form Scale (BSFS). Written, informed consent.
-
○Screening period: 14 ± 3 days. A “run‐in” phase under full trial conditions, to ensure familiarization and compliance with study protocols.
-
○
- Visit 2 In‐Clinic: Verification of IBS diagnosis and subtype, collection of baseline symptom data and biochemical testing. Eligible patients randomized to receive 15 mL of silicolgel or placebo three times a day for 4 weeks. Patients could take treatment undiluted or diluted with water, at least 1 h before meals, with at least a 1‐h gap between taking treatment and other medications– (Day 1).
-
○Treatment period: 28 ± 3 days. Silicolgel is a type II medical device recommended for continuous usage for 4 weeks. A break of a few days is required before dosage can be continued.
-
○
- Visit 3 In‐Clinic: Assessment of efficacy, safety, and tolerability of treatments. Key biochemical tests for comparison with Visits 1/2. Collection of unused medication– (29 ± 3 days).
-
○Observation phase: 28 ± 3 days. Patients were asked to undergo an additional 4‐week period without medication to determine delayed effects of treatments and if/when symptoms returned.
-
○
Visit 4 In Clinic: Assessment of delayed/carry over effects of therapy (56 ± 6 days).
Patients were not allowed to take IBS medications during the study. Mebeverine and Loperamide were permitted “escape medication” if symptoms became very severe. The use of these was recorded by the patient and the investigator.
In‐clinic visits included physical examination of the patient, vital functions, general well‐being, adverse events, and treatment tolerability.
2.2. Data Collection, Assessment Methods, and Study Outcomes
See Tables S2 and S3 for full details.
2.2.1. Francis et al. [35] IBS SSS Questionnaire
Patients completed this questionnaire weekly for the following.
Primary outcome
Reduction in IBS SSS by ≥ 50 points after 4 weeks of treatment (number and % of patients): a reduction of ≥ 50 points in a patient's IBS SSS is an established indicator of clinically meaningful improvement of IBS symptoms. The maximum IBS SSS score is 500. A patient is classified as having Severe IBS if the IBS SSS is > 300, Moderate IBS if it is between 175 and 300, Mild IBS if it is between 75 and 174, and in remission if it is < 75.
Secondary IBS SSS outcomes
Reduction of ≥ 100 points in IBS SSS after 4 weeks of treatment.
Change in IBS SSS after 4 weeks of treatment.
2.2.2. Patient Daily Diaries
Other secondary outcomes were assessed using Patient Daily Diaries for:
Bowel habit: number and type (BSFS) of stools recorded each day.
Severity of IBS symptoms: abdominal pain, distension, bloating, and flatulence. These symptoms were assessed using this VAS:
![]()
The severity of other GI symptoms was also recorded using this 0%–100% VAS.
Quality of Life due to IBS:
Three QoL‐related questions were patient‐assessed:
“Satisfaction with Frequency and Nature of Defecation.” Using this VAS:
![]()
“Impact of IBS on the patient's quality of life.” This VAS was used:
![]()
“Effect of the Treatment on IBS as a whole and on the patient's self‐confidence.”
![]()
European Medicines Agency (EMA)/FDA composite measure for IBS‐D [36]. (This is the number and % of patients achieving a reduction in abdominal pain of ≥ 30% and ≥ 50% reduction in frequency of loose stools per week).
Weekly questionnaires and Daily Diaries were verified by the investigators at in‐clinic visits.
2.3. Participants
Patients aged 18–60 years had to meet ROME IV criteria for IBS‐D or IBS‐M and an extensive range of other criteria, including (see Table S1 for detailed inclusion/exclusion criteria):
Exclusion: Use of intestinal adsorbents, coeliac disease, inflammatory bowel disease, and bowel cancer/resection. “Red flag” symptoms.
Inclusion: From the list of symptoms (diarrhea, abdominal pain, distension/bloating, and flatulence), four occurred monthly, two occurred weekly, and one occurred twice a week. At least 25% of stools corresponded to type 6 or 7 (BSFS) and the severity of IBS on the IBS‐SSS score ranged from 100 to 400 points.
2.4. Investigational Medical Device
Silicolgel is a colloidal silicic acid gel with finely and evenly dispersed particles in a stable suspension that can physically adsorb/bind organic molecules to the particle surface. Silicolgel works locally in the gut and is not absorbed into the bloodstream. It acts solely by physical, not pharmacological action and therefore is defined as a medical device.
Medical devices are categorized into different risk classes, with classification determining the regulatory pathway required to market the device. Class I devices are considered low risk and are self‐certified. Class IIa devices, which are low/medium risk, and Class IIb devices, which are medium or higher risk, require accreditation by a notified body before they can be marketed. They are then subject to annual audit and routine updates to demonstrate safety and efficacy in use.
Silicolgel is a CE‐marked class IIb medical device (MDR EU 2017/745) [37].
Longer term usage: Silicolgel can be taken as a treatment for IBS for up to 4 weeks. If symptoms have not improved, the patient should consult a physician. If symptoms are under control, patients should take a break of a few days before they begin another course of treatment.
2.5. Placebo
As the majority of thickening agents affect the GI tract, developing a gel‐consistency placebo was challenging. Therefore, the placebo used in this study was pure water with a low level of white colorant to make it appear visually very similar to silicolgel but more watery.
2.6. Randomization and Blinding
Randomization and treatment allocation was masked for both patients and investigators. Unblinding occurred only after the data manager and statistician completed the analysis and confirmed database closeout.
At Visit 2 In‐Clinic, eligible patients were randomized by a telephone call to the independent (C.R.O.) coordinator in charge of the randomization.
Randomization was in a ratio of 1:1 into two groups (60 patients in each group). This was conducted via telephone blocks, comprising different block sizes, ensuring allocation concealment. Stratification was carried out using site number and IBS subtype.
The randomization scheme was created using https://www.sealedenvelope.com/simple‐randomiser/v1/lists, seed 193607437957995, and the Investigational Product Decoding Scheme was created using the Microsoft Excel pseudo‐random generator. Both schemes were kept by the Sponsor and the C.R.O. and were not transferred to the study sites. Before randomization and throughout the study, the association between the randomization number and investigational product code was unknown to investigators and patients.
Silicolgel and placebo were delivered to each site in identical opaque, plain bottles with pilfer‐proof closures preventing premature opening or mishandling, and the treatment could not be seen until opened for first use. Label and patient leaflet information for both treatments was identical, and the only distinction was unique investigational product codes. Product codes were labeled on each bottle, and this was the same for every eight bottles intended for one patient.

Patients were assigned and given their treatment bottles in‐clinic but did not open any bottle or commence dosage until they were off site, to ensure investigators did not see the appearance of treatments. Thus neither patient nor investigator knew which treatment was assigned.
2.7. Statistical Methods
The statistical plan was finalized before trial commencement and data analysis.
The required sample size was calculated using the universal sample size formula calculation:
The estimate for silicolgel response rate was based upon two previous silicolgel studies: an early (unpublished) clinical trial and the open‐label post‐marketing study published in 2023 [34]. This 2023 study showed an 83.6% response rate (ITT) and 87.7% for all those who completed the study.
Published IBS studies were used for estimating response rates in the placebo group (ranging from 20% to 70%) [38]. From this literature, we assumed a typical placebo effect in IBS trials (P c) of 55%.
We assumed the response rate for silicolgel (P t) (placebo effect plus active effect) would be 55% + 25% = 80% (compared to 83.6% and 87.7% in the 2023 study).
For tests of superiority in efficacy, it is generally accepted to adopt a 95% confidence level, that is α = 0.05 (5%), and the probability of making an error of the second type β = 0.2 (20%), which allows this study to have a statistical power of 0.8 (80%).
As there is no universally recognized effective treatment for IBS, the detection of statistically significant differences from the placebo group in the direction of increased effect is clinically significant. Therefore, δ0 = 0 in the calculation.
At a 95% significance level and a POWER of 80%, the sample size calculation was 53 in each treatment group. An assumed drop‐out rate of 12% equated to 60 patients per group.
In this study, the response rate for silicolgel (P t) was actually 91.67%, and for placebo (P c) 20.00%. With 60 patients completing the study in each leg, the actual POWER calculation for this trial equates to greater than 90%.
Normality of distribution for all datasets was tested with Shapiro–Wilk and/or Kolmogorov–Smirnov tests. Analyses were conducted following the intention‐to‐treat (ITT) principle.
For assessment of efficacy within each treatment group, a paired Student's t‐test was used to generate quantitative parameters and 95% confidence intervals for normally distributed data. For nonparametric data, a Wilcoxon‐signed rank test with false discovery rate correction was used.
For the comparison of efficacy between silicolgel and placebo groups, a two‐sample Student's t‐test was used to generate quantitative parameters for normally distributed data. If the data were distributed nonparametrically, a Mann–Whitney U‐test was used.
For categorical efficacy variables, results in groups were compared using the chi‐square test or the two‐sided Fisher's exact test. Effect size as relative risk (RR) and Cohen's d were also used.
3. Results
The study commenced on March 15, 2023 with first patient Clinic Visit 1, with last patient Clinic Visit 4 on August 31, 2023.
3.1. Study Participants
In total, 139 potentially eligible volunteers with IBS were screened. Ninteen patients not meeting study criteria were excluded (see Figure 2).
FIGURE 2.

CONSORT flow diagram showing the distribution of patients in the study.
At Visit 2 in‐clinic, the remaining 120 patients were randomized to silicolgel (n = 60) and placebo (n = 60). All 120 patients completed the 4‐week treatment period to Visit 3 in‐clinic, and all 120 patients presented to Visit 4 in‐clinic. However, at Visit 4, although 119 of 120 patients had fully completed weekly questionnaires and daily diaries for Weeks 1, 2, and 3 of the Observation phase, most patients returned Week 4 as blank, with only 12 patients on silicolgel and 11 on placebo providing part‐complete diary data for Week 4.
Where (limited) data for Week 4 are available, this is reported. The last observation carried forward procedure is not appropriate as it results in underestimation. Therefore, for most outcomes the Observation phase ends at Week 3.
Reasons for blank diaries for Observation Week 4 were unclear. Some investigators suggested that symptoms had returned after 4 weeks and patients were reluctant to continue with no medication for their IBS.
3.2. Baseline Characteristics
Patients in both groups were compared for age, gender, weight, height, BMI, IBS type, disease history at screening, frequency and severity of common IBS symptoms, other associated GI symptoms, and IBS SSS scores.
The two groups were homogeneous, and baseline characteristics are shown in Table 1.
TABLE 1.
Baseline characteristics of the study population.
| Baseline characteristics | Total cohort | Silicolgel group | Placebo group |
|---|---|---|---|
| (N = 120) | (n = 60) | (n = 60) | |
| Gender, n (%) | |||
| Female | 79 (66%) | 42 (70%) | 37 (62%) |
| Male | 41 (34%) | 18 (30%) | 23 (38%) |
| Age, years; mean (range) | 36.9 (18–70) | 36.6 (18–67) | 37.2 (19–70) |
| BMI, mean (range) | 24.1 (20.0–30.4) | 23.99 (20.0–30.4) | 24.25 (20.8–29.5) |
| IBS subtypes, n (%) | |||
| IBS‐D | 53 (44%) | 26 (43%) | 27 (45%) |
| IBS‐M | 67 (56%) | 34 (57%) | 33 (55%) |
| IBS severity by IBS SSS, n (%) | |||
| > 300 (severe) | 28 (23%) | 14 (23.3%) | 14 (23.3%) |
| 175‐300 (moderate) | 85 (71%) | 42 (70.0%) | 43 (71.7%) |
| 75–174 (mild) | 7 (6%) | 4 (6.7%) | 3 (5.0%) |
| Mean IBS SSS visit 2 | 255.02 [49.48] | 255.62 [50.59] | 254.42 [48.77] |
| Baseline, [SD], range | 130–360 | 130–360 | 130–360 |
| IBS‐D | 270.51 [49.90] | 270.65 [56.50] | 270.74 [43.76] |
| IBS‐M | 242.99 [46.02] | 244.12 [42.93] | 241.06 [49.21] |
Abbreviations: BMI, body mass index; IBS, irritable bowel syndrome; IBS SSS, irritable bowel syndrome severity scoring system; IBS‐D, irritable bowel syndrome with predominant diarrhea; IBS‐M, irritable bowel syndrome with mixed bowel habits; SD, standard deviation.
3.3. Protocol Variations
A total of 119 deviations from protocol were recorded in 97 patients, including four significant deviations in three patients. All deviations were listed and categorized by the statistician before unblinding (see Table 2).
TABLE 2.
Protocol deviations.
| Group | ||
|---|---|---|
| Silicolgel | Placebo | |
| Description of deviation from the protocol (significant deviations) | ||
| Noncompliance with inclusion criterion no. 2 (age over 60 years) | 1 | 1* |
| Increased fecal calprotectin more than 150 μg/g (*177 μg/g) | — | 1* |
| Taking prohibited self‐medication during observation phase | 1 | — |
| Total | 2 | 2 |
| Description of deviation from the protocol (nonsignificant deviations) | ||
| Missing silicolgel/placebo doses (1 to max 10) | 35 | 41 |
| The duration of the run‐in period is less than the permissible one | 6 | 9 |
| Failure to perform a breath test on the third visit | 6 | 5 |
| The duration of the silicolgel/placebo course is 1 day less than allowed | 1 | 2 |
| The interval between 2 and 3 visits exceeds the permissible interval | 2 | 1 |
| The patient did not return the bottles with residual silicolgel/placebo | 1 | 2 |
| Retest of general blood analysis in a local laboratory | — | 1 |
| Conducting a blood test for pregnancy in a menopausal patient | 1 | — |
| Failure to conduct blood and urine tests at the third visit | — | 1 |
| Transfer of blood and urine tests from the third to the final visit | — | 1 |
| Total | 52 | 63 |
Same patient.
Three patients completed the study with four significant deviations from protocol: one patient was aged 67 (permitted age 18–60), one patient was aged 70 and had fecal calprotectin at 177.7 μg/g (acceptable up to 150). Also, one patient took self‐medication likely to have a GI effect during the Observation (no‐medication) phase.
These deviations did not prevent key study objectives or results analysis. Considering the effect size changes achieved and the nature of these deviations, inclusion/exclusion of these three patients did not affect study results and conclusions.
Nonsignificant protocol variations were missed doses, slightly longer/shorter duration between in‐clinic visits, and missed biochemical tests at Visit 3.
None of the protocol variations, including missing data for Observation Week 4, were considered sufficient to require exclusion of a patient from the study.
Therefore, all 120 randomized patients are included in the “per protocol” population, and per protocol and intention‐to‐treat populations do not differ.
3.4. Results of Key Outcomes
The full details, with statistics, are provided in Table 3.
TABLE 3.
Results for key outcomes.
| Outcome | Silicolgel | Placebo | Effect size | p |
|---|---|---|---|---|
| Primary outcome | ||||
| IBS SSS: No. & (%) achieving a reduction of ≥ 50 | ||||
| After Week 1 of treatment (ITT n = 120) |
29/60 (48.3%) |
4/60 (6.7%) |
ARR = 41.7%, CI = 27.5%–55.8% RR = 7.25, CI = 2.71–19.36 NTT = 2.49 (3) (1.79–3.63) |
0.0001 |
| After Week 2 of treatment (ITT n = 120) |
51/60 (85.0%) |
7/60 (11.67%) |
ARR = 73.30%, CI = 61.2%–85.5% RR = 7.28, CI = 3.60–14.74 NTT = 1.36 (2) (1.17–1.63) |
< 0.0001 |
| After Week 3 of treatment (ITT n = 120) |
53/60 (88.3%) |
15/60 (25.0%) |
ARR = 63.3%, CI = 49.7%–77.0% RR = 3.53, CI = 2.25–5.53 NTT = 1.58 (2) (1.30–2.01) |
< 0.0001 |
| After 4 weeks of treatment | ||||
| ITT n = 120 |
55/60 (91.67%) |
12/60 (20.0%) |
ARR = 71.67%, CI = 59.36%–83.97% RR = 4.58, CI = 2.74–7.65 NTT = 1.39 (2) (1.19–1.69) |
< 0.0001 |
| IBS Type D n = 53 |
23/26 (88.5%) |
5/27 (18.5%) |
ARR = 69.94%, CI = 50.82%–89.06% RR = 4.77, CI = 2.14–10.67 NTT = 1.43 (2) (1.12–1.97) |
< 0.0001 |
| IBS Type M n = 67 |
32/34 (94.1%) |
7/33 (21.2%) |
ARR =72.91%, CI = 56.87%–88.94% RR = 4.44 CI = 2.28–8.61 NTT = 1.37 (2) (1.12–1.76) |
< 0.0001 |
| Secondary outcomes | ||||
| IBS SSS: No. & (%) achieving a reduction of ≥ 100 after 4 weeks treatment | ||||
| (ITT n = 120) |
51/60 (85.0%) |
5/60 (8.3%) |
ARR = 76.67%, CI = 65.24%–88.09% RR = 10.20, CI = 4.38–23.77 NTT = 1.30 (2) (1.13–1.53) |
< 0.0001 |
| IBS Type D (n = 53) |
21/26 (80.8%) |
3/27 (11.1%) |
ARR = 69.66%, CI = 50.42%–88.89% RR = 7.27, CI = 2.46–21.48 NTT = 1.44 (2) (1.12–1.98) |
0.0003 |
| IBS Type M (n = 67) |
30/34 (88.2%) |
2/33 (6.1%) |
ARR = 82.17%, CI = 68.63%–95.72% RR = 14.56, CI = 3.78–56.10 NTT =1.22 (2) (1.04–1.46) |
0.0001 |
| Mean IBS SSS [SD] After 4 weeks of treatment (ITT n = 120) | ||||
| Baseline |
255.62 [50.59] |
254.42 [48.77] |
No Sig Diff | 0.971 |
| After 4 weeks of treatment |
92.75 [62.68] |
257.58 [74.94] |
Mann–Whitney U = 210.5, r = 0.76 Cohen's d = 2.38 |
< 0.001 |
| Change versus baseline |
−162.87 [82.98] |
+3.17 [61.91] |
Mann–Whitney U = 237.5, r = 0.75 | < 0.001 |
|
Abdominal pain: Frequency: number of days with abdominal pain in the last 10 days (ITT = 120) | ||||
| Baseline |
5.10 [1.60] |
5.27 [1.80] |
No Sig Diff | 0.608 |
| After 4 weeks of treatment |
2.22 [2.43] |
6.07 [2.24] |
Mann–Whitney U = 462. r = 0.65 Cohen's d = 1.65 |
< 0.001 |
|
Abdominal pain: Mean severity: (0%–100% VAS higher = more severe) (ITT n = 120) | ||||
| Baseline |
48.58 [10.82] |
48.75 [13.55] |
No Sig Diff | 0.785 |
| After 4 weeks of treatment |
12.83 [11.36] |
42.42 [18.72] |
Mann–Whitney U = 333, r = 0.71 Cohen's d = 1.91 |
< 0.001 |
|
Abdominal pain: ≥ 30% reduction in abdominal pain score: (No and % achieving) ITT n = 120 | ||||
| No. & % achieving after Week 1 treatment |
27/60 (45.0%) |
9/60 (15.0%) |
ARR = 30.00%, CI = 14.51%–45.50% RR = 3.00, CI = 1.54–5.83 NTT = 3.33 (4) (2.20–6.90) |
0.001 |
| No. & % achieving after Week 2 treatment |
46/60 (76.7%) |
11/60 (18.3%) |
ARR = 58.33%, CI = 43.83–72.84 RR = 4.18, CI = 2.41–7.26 NTT = 1.71 (2) (1.37–2.28) |
< 0.001 |
| No. & % achieving after Week 3 treatment |
50/60 (83.3%) |
18/60 (30.0%) |
ARR = 53.30%, CI = 38.39%–68.28% RR = 2.78, CI = 1.86–4.16 NTT = 1.87 (2) (1.46–2.61) |
< 0.001 |
| No. & % achieving after 4 weeks of treatment |
52/60 (86.7%) |
16/60 (26.7%) |
ARR = 60.00%, CI = 45.89%–74.11% RR = 3.25, CI = 2.11–5.00 NTT = 1.67 (2) (1.35–2.18) |
< 0.001 |
|
Bowel habit: Mean [SD] no of days with loose stools per week (BSFS 6–7) ITT n = 120 | ||||
| Baseline |
3.95 [1.86] |
3.78 [1.75] |
No Sig Diff | 0.614 |
| After 4 weeks of treatment |
0.58 [1.33] |
2.48 [2.12] |
t = 5.880, mean difference = 1.90, 95% CI 1.26–2.54 Cohen's d = 1.07 |
< 0.001 |
|
Bowel habit: ≥ 50% reduction in days with loose stools per week (No and % achieving) ITT n = 120 | ||||
| No. & % achieving after Week 1 treatment |
44/60 (73.3%) |
26/60 (43.3%) |
ARR = 30.00%, CI = 13.19%–46.81% RR = 1.69, CI = 1.22–2.35 NTT = 3.33 (4) (2.14–7.58) |
0.002 |
| No. & % achieving after Week 2 treatment |
54/60 (90.0%) |
25/60 (41.7%) |
ARR = 48.30%, CI = 33.73%–62.94% RR = 2.16, CI = 1.58–2.95 NTT = 2.07 (3) (1.59–2.97) |
< 0.001 |
| No. & % achieving after Week 3 treatment |
56/60 (93.3%) |
27/60 (45.0%) |
ARR = 48.30%, CI = 34.25%–62.42% RR = 2.07, CI = 1.55–2.77 NTT = 2.07 (3) (1.60–2.92) |
< 0.001 |
| No. & % achieving after 4 weeks of treatment |
56/60 (93.3%) |
28/60 (46.7%) |
ARR = 46.70%, CI = 32.55%–60.78% RR = 2.00, CI = 1.51–2.64 NTT = 2.14 (3) (1.64–3.07) |
< 0.001 |
|
EMA/FDA composite measure: Achieve both ≥ 30% abdominal pain reduction & ≥ 50% reduction in loose stools per week (ITT n = 120) | ||||
| No. & % achieving after Week 1 treatment |
23/60 (38.3%) |
9/60 (15.0%) |
ARR = 23.30%, CI = 8.07%–38.60% RR = 2.56, CI = 1.29–5.06 NTT = 4.29 (5) (2.59–12.39) |
0.007 |
| No. & % achieving after Week 2 treatment |
44/60 (73.3%) |
10/60 (16.7%) |
ARR = 56.67%, CI = 42.03%–71.30% RR = 4.40, CI = 2.45–7.91 NTT = 1.76 (2) (1.40–2.38) |
< 0.0001 |
| No. & % achieving after Week 3 treatment |
50/60 (83.3%) |
18/60 (30.0%) |
ARR = 53.30%, CI = 38.39%–68.28% RR = 2.78, CI = 1.86–4.16 NTT = 1.88 (2) (1.46–2.61) |
< 0.0001 |
| No. & % achieving after Week 4 treatment | ||||
| ITT (n = 120) |
51/60 (85.0%) |
14/60 (23.3%) |
ARR = 61.70%, CI = 47.66%–75.67% RR = 3.64 CI = 2.27–5.83 NTT = 1.62 (2) (1.32–2.10) |
< 0.0001 |
| IBS‐D (n = 53) |
19/26 (73.1%) |
5/27 (18.5%) |
ARR = 54.60%, CI = 32.98%–77.04% RR = 3.95, CI = 1.73–9.00 NTT = 1.83 (2) (1.30–3.11) |
0.0011 |
| IBS‐ M (n = 67) |
32/34 (94.1%) |
9/33 (27.3%) |
ARR = 66.80%, CI = 49.71%–83.98% RR = 3.45, CI = 1.96–6.06 NTT = 1.50 (2) (1.19–2.00) |
< 0.0001 |
| Quality of life: mean severity 0%–100% on VAS, where higher = more (ITT n = 120) | ||||
| ||||
| Baseline |
56.08 [14.85] |
51.92 [11.39] |
No sig diff | 0.128 |
| After 4 weeks of treatment |
22.33 [12.90] |
54.75 [13.70] |
Mann–Whitney U = 203.5, r = 0.77 Cohen's d = 2.43 |
< 0.001 |
|
||||
| Baseline |
55.87 [15.77] |
53.17 [12.25] |
No Sig Diff | 0.325 |
| After 4 weeks of treatment |
21.00 [13.21] |
55.25 [14.83] |
Mann–Whitney U = 226.5, r = 0.76 Cohen's d = 2.44 |
< 0.001 |
| ||||
| Baseline |
52.42 [11.98] |
48.00 [8.74] |
Mann–Whitney U = 1456, r = 0.19 Cohen's d = 0.42 |
0.038 |
| After 4 weeks of treatment |
77.83 [17.40] |
50.25 [15.69] |
Mann–Whitney U = 356, r = 0.70 Cohen's d = 1.66 |
< 0.001 |
| Abdominal distension—mean severity: (0%–100% VAS) (ITT n = 120) | ||||
| Baseline |
44.08 [17.28] |
47.92 [16.76] |
No Sig Diff | 0.22 |
| After 4 weeks of treatment |
14.42 [13.25] |
44.50 [18.70] |
Mann–Whitney U = 359, r = 0.70 Cohen's d = 1.86 |
< 0.001 |
| Abdominal Bloating—mean severity: (0%–100% VAS) ITT n = 120 | ||||
| Baseline |
43.92 [19.83] |
49.25 [15.73] |
No Sig Diff | 0.158 |
| After 4 weeks of treatment |
15.00 [12.42] |
44.92 [20.12] |
Mann–Whitney U = 429, r = 0.67 Cohen's d = 1.79 |
< 0.001 |
| Flatulence—mean severity: (0%–100% VAS higher = more severe) (ITT = 120) | ||||
| Baseline |
45.17 [20.85] |
50.83 [20.26] |
No Sig Diff | 0.151 |
| After 4 weeks of treatment |
15.42 [11.06] |
47.83 [20.65] |
Mann–Whitney U = 335.5, r = 0.71 Cohen's d = 1.96 |
< 0.001 |
Note: Mann–Whitney U‐test: r = effect size where r < 0.1 no effect/very small effect, r = 0.1 small effect, r = 0.3 medium effect, r > 0.5 large effect. Cohen's d: standardized Mean difference: ≤ 0.2 = small, 0.5 = medium, ≥ 0.8 = large (DATAtab Team (2025) used for calculation).
Abbreviations: ARR, absolute risk reduction; BSFS, Bristol Stool Form Scale; CI, 95% confidence intervals; EMA, European Medicine Agency; FDA, Food and Drug Administration; IBS‐D, irritable bowel disease with predominant diarrhea; IBS‐M, irritable bowel syndrome with mixed bowel habits; ITT, intention‐to‐treat; NTT, number needed to treat; RR, relative risk.
3.4.1. Primary Outcome—A Reduction in IBS SSS Score of ≥ 50
After 4 weeks of treatment, the primary outcome was achieved by 55 out of 60 patients (91.67%) in the silicolgel group, compared to 12 out of 60 (20.00%) patients in the placebo group (RR = 4.58, 95% CI 2.74–7.65, NTT = 1.39 (2) (1.19–1.69), p < 0.0001).
The onset of action was rapid. After 2 weeks of treatment, the primary outcome was achieved by 51 out of 60 patients (85.00%) in the silicolgel group compared to 7 out of 60 (11.67%) patients in the placebo group (RR = 7.28, 95% CI 3.60–14.74, p < 0.0001).
IBS subtypes: After 4 weeks of treatment, IBS‐D (n = 53), 23/26 (88.5%) patients on silicolgel achieved the primary outcome versus 5/27 (18.5%) on placebo (RR = 4.77, 95% CI 2.14 to 10.67, p < 0.0001). For the IBS‐M subtype (n = 67), 32/34 (94.1%) on silicolgel compared to 7/33 (21.2%) on placebo achieved the primary outcome (RR = 4.44, 95% CI 2.28–8.61, p < 0.0001).
3.4.2. Secondary Outcomes—Other IBS SSS Measures
3.4.2.1. A Reduction of ≥ 100 IBS SSS
After 4 weeks of treatment, 85.0% in the silicolgel group versus 8.3% in the placebo group achieved this outcome (RR = 10.20, 95% CI 4.38–23.77, p < 0.0001). Similar results were observed for IBS‐D and IBS‐M subtypes.
3.4.2.2. Change in Mean IBS SSS
At Screening (Visit 1) and Baseline (Visit 2), there was no significant difference between silicolgel and placebo groups. After 1‐week treatment, mean IBS SSS of the silicolgel group reduced from 255.62 at baseline to 200.00 (–55.62) whereas the placebo group was unchanged (silicolgel significantly lower than placebo; t (118) = −5.65, 95% CI −81.4, −39.1, p < 0.001; Figure 3).
FIGURE 3.

Mean IBS SSS in the silicolgel and placebo groups throughout the study. IBS SSS, irritable bowel syndrome severity scoring system; ITT, intention‐to‐treat; 95% CI = 95% Confidence Intervals.
After 4 weeks of treatment, mean IBS SSS of the silicolgel group was 92.75 (−162.87) compared to 257.62 (+3.17) for placebo (Mann–Whitney U = 210.5, r = 0.76, p < 0.001).
The change in mean IBS SSS from 255.62 at baseline to 92.75 (−162.87) after 4 weeks of treatment represented a change in IBS status: Moderate IBS to Mild IBS [35].
Changes in the mean IBS SSS scores were similar in patients with IBS‐D and IBS‐M subtypes, and these reductions were also significant (see Figure S1).
After treatments were stopped, mean IBS SSS of the silicolgel group increased as symptoms returned, remaining below the baseline level through to Week 3 of the observation period.
3.4.3. Secondary Outcome—Abdominal Pain
3.4.3.1. Abdominal Pain Frequency (Days Suffered in Last 10 Days)
Silicolgel and placebo groups were not significantly different at baseline (Visit 2). After 4 weeks of treatment, silicolgel group mean frequency reduced from 5.10 days at baseline to 2.22 days. By comparison, the placebo group frequency slightly increased to 6.07 days. The difference between silicolgel and placebo groups was significant.
3.4.3.2. Abdominal Pain Severity
Silicolgel and placebo groups were not significantly different at screening (Visit 1) and baseline (Visit 2) and both at “Quite Severe” on the VAS. From Week 1 of treatment through to Week 3 of observation, the silicolgel group had a significantly lower severity than the placebo group. The symptom gradually returned during the no‐medication period (see Figure 4).
FIGURE 4.

Abdominal pain: mean severity scores throughout the study.
3.4.3.3. ≥ 30% Reduction in Abdominal Pain Score, After 4 Weeks of Treatment
In the silicolgel group, 52 out of 60 patients (86.7%) achieved this outcome. In the placebo group, 16 out of 60 (26.7%) achieved this reduction in pain (significant difference).
3.4.4. Bowel Habit
3.4.4.1. ≥ 50% Reduction in Loose Stools Per Week
After 4 weeks of treatment, in the silicolgel group, 56 out of 60 patients (93.3%) achieved this reduction in loose stools. By comparison, in the placebo group this was 28 out of 60 (46.70%); significant difference).
3.4.4.2. Mean Days Per Week With Loose Stools
At baseline (Visit 2) there was no significant difference between silicolgel and placebo groups. During treatment, both groups showed reductions in loose stools, with the silicolgel group significantly lower than placebo from Week 1 of treatment onward.
After 4 weeks of treatment, days with loose stools in the silicolgel group reduced from 3.95 days per week to 0.58 days. In the placebo group, days with loose stools reduced from 3.78 days per week to 2.48 days. The difference between silicolgel and placebo groups was significant (t = 5.88, difference of means = 1.90, SE = 0.32, 95% CI = 1.26–2.54, p < 0.001; see Figure 5).
FIGURE 5.

Bowel habit: mean number of days with loose stools (Bristol Stool Form Scale 6–7) per week.
During the observation (no‐medication) period, days with loose stools increased in both groups, and by Week 3 of observation, there was no significant difference between the two groups. At Week 4 observation, the limited data indicated loose stools frequency had returned to baseline levels.
IBS Subtypes IBS‐D and IBS‐M showed similar results (see Figure S2).
3.4.5. EMA Composite Efficacy Measure [36]
A significantly greater number of patients achieved this composite measure in the silicolgel group versus the placebo group from Week 1 of treatment onward. After 4 weeks of treatment, 51 out of 60 patients (85.0%) in the silicolgel group achieved this measure compared to 14 out of 60 (23.3%) in the placebo group (significant difference).
Results were the same for the IBS‐D subtype: 19/26 (73.1%), versus 5/27 (18.5%) respectively and for the IBS‐M subtype: 32/34 (94.1%), versus 9/33 (27.3%) respectively.
3.4.6. Quality of Life
Satisfaction with frequency and nature of defecation: (on a 0%–100% VAS).
At baseline, mean severity scores for silicolgel and placebo groups were not significantly different at 56.08% and 51.92%, respectively; these equating to “Dissatisfied” on the VAS.
After 4 weeks of treatment, the silicolgel group reduced to a mean of 22.33% “Very Satisfied/Satisfied Enough” on the VAS. Placebo group was unchanged at 54.75%. There was a significant difference between silicolgel and placebo.
-
ii
Impact of IBS on QoL: (0%–100% VAS).
Mean severity scores for silicolgel and placebo groups were not significantly different at baseline (55.87% and 53.17%); these equated to “Significantly Affects QoL” on the VAS.
After 4 weeks of treatment, the silicolgel group reduced to a mean of 21.00% “Does Not Affect at all/Slightly Affects QoL” on the VAS. Placebo group was unchanged on 55.25%, there was a significant difference between silicolgel and placebo.
-
iii
Impact of the IBS treatment on QoL: (0%–100% VAS).
At baseline, mean scores for silicolgel and placebo were significantly different (p = 0.038) at 52.42% and 48.00%. The reason for this difference before treatment is not clear although both groups equated to “Unchanged” on the VAS.
After 4 weeks of treatment, the silicolgel group mean increased to 77.83% “Slight Improvement/Significant Improvement” on the VAS. By comparison, the placebo mean was 50.25% “Unchanged.” There was a significant difference between silicolgel and placebo.
The effect of silicolgel on the three QoL measures can be seen in Figure 6.
FIGURE 6.

Mean scores for the three quality of life measures in the silicolgel group. 95% CI = 95% Confidence Intervals.
For results of the Placebo group—see Figure S3. The IBS‐D and IBS‐M subtypes had the same results as the total cohort—see Figure S4.
3.4.7. Abdominal Distension, Bloating, and Flatulence
At baseline, at least 65 out of 120 patients reported each of these three symptoms rated at least 50% (“Quite Severe”) on the VAS. In this study population these three symptoms were common and problematic.
Significant reductions in mean severity scores for abdominal distention (increase in girth), bloating (feeling of fullness), and flatulence were observed from baseline to Week 4 of treatment with silicolgel. The placebo group showed no changes in the mean severity of all three of these symptoms after 4 weeks of treatment. There were significant differences between silicolgel and placebo for these symptoms from Week 1 onward (see Table 3, Figures S5–S7).
For all outcomes, the pattern of change during the 4‐week treatment period was similar, with the silicolgel group significantly improved versus placebo. During the no‐medication observation period, symptoms started to return. Data trends suggest that most of the symptoms would have returned to baseline/pre‐treatment levels after 4 weeks with no medication. Patient subgroups IBS‐D and IBS‐M showed similar responses to the total cohort.
3.4.8. Other GI Symptoms (Heartburn, Regurgitation/Reflux, Belching, and Nausea)
These symptoms are occasionally reported by IBS sufferers. The objective was to record these and any effect from the treatments.
In this study population, these symptoms were not common or severe. However, in those patients who did report these symptoms, a reduction in symptom severity was observed after 4 weeks of treatment with silicolgel, whereas there was no change with the placebo group.
3.5. Safety and Tolerability
All 120 patients who received treatments were included in the safety analysis. During the study, 13 cases of mild, nonserious adverse events were registered in 10 patients (6 placebo, 4 silicolgel) at the Chernivtsi Site. All cases were deviations of blood tests from laboratory norms. All these adverse events resulted in complete recovery (without consequences), confirmed by the results of the next laboratory analysis. For all cases of adverse events, relation to intake of silicolgel or placebo was assessed as absent by the investigator.
There were no treatment discontinuations due to adverse events, individual intolerance, or hypersensitivity to ingredients, demonstrating the tolerability of silicolgel and the placebo.
4. Discussion
In this clinical trial, 91.67% of silicolgel users achieved the primary outcome (≥ 50 reduction in IBS SSS) compared to 20.00% on placebo. For the silicolgel group, the reduction in mean IBS SSS of −162.87, from moderate IBS to mild IBS, was significant. Similarly, silicolgel users reported significant improvements in bowel habit, abdominal pain, distension, bloating, flatulence, and QoL. Onset of action in the silicolgel group was rapid. Patients reported some improvements after just 1 week, and the majority of patients in the silicolgel group recorded significant improvement in their IBS after 2 weeks.
As expected from a medical device which has been marketed for over 10 years in the UK and EU with an excellent safety record, the safety and tolerability of silicolgel in this study were excellent.
Silicolgel post‐marketing study: This open‐label study published in 2023 [34] showed that silicolgel effectively and safely improved the overall IBS status of patients with IBS‐D and IBS‐M in normal usage. After 4 weeks of treatment with silicolgel, IBS SSS mean scores reduced by −163.1, and 84% (ITT) of participants showed a reduction of ≥ 50 IBS SSS points. There were also significant reductions in common IBS symptoms and improvements in QoL with silicolgel. Improvement in symptoms was observed from Week 1 of treatment with silicolgel. Results from the 2023 silicolgel study [34] fully support the findings of this current double‐blind, placebo‐controlled clinical trial, both qualitatively and quantitatively.
Comparison with other enterosorbent studies: The response rate for silicolgel in this current study at 91.67% is high, although among participants who completed the full 4 weeks of silicolgel treatment in the open‐label study [34] the response rate was similar at 87.7%.
The 2022 IBS trial by Howell et al. [23] on IBS‐D patients and using a different primary measure did report some IBS SSS data and used a synthetic organosilicon enterosorbent similar to silicolgel. During Weeks 5–8 of their study, they reported a change in mean IBS SSS scores from 334.4 at baseline to 184.5, a reduction of −149.9, comparable to the reduction in both this silicolgel trial and in the open‐label silicolgel study published in 2023.
The placebo response rate of 20.0% in this current silicolgel study is at the lower end of published IBS studies. However, in the only other large‐scale IBS clinical trial of an enterosorbent, by Howell et al. in 2022 [23], their placebo response rate was a comparable 24.3%.
Also, in this silicolgel study 12 of 60 (20.0%) patients on placebo showed a reduction of ≥ 50 in their IBS SSS, 9 patients recorded a lesser reduction in IBS SSS, and 3 were unchanged. However, the majority 36 out of 60: (60.0%) experienced an increase in their IBS SSS. This is perhaps not surprising, as recruitment was via IBS clinics where most patients would have routinely taken some IBS medication. During this study, patients were not allowed to take other IBS medication (except escape medication) and the placebo was ineffective, possibly explaining why many taking placebo showed worsening symptoms.
Comparison with other IBS therapies: Current guidelines for the treatment of IBS recommend dietary management (e.g., FODMAP), regular exercise, and probiotics. Other options include pharmacological and psychological interventions; however, the evidence supporting these therapies is inconsistent. Additionally, some drugs appear to provide inadequate relief, have safety concerns, high costs, and limited availability [1, 39, 40, 41, 42, 43, 44, 45, 46].
More effective therapies are urgently needed given the prevalence of IBS, its detrimental effect on QoL, and its cost to healthcare systems. Also, in a large survey less than one‐third of patients with IBS were satisfied with their current therapy [39] and 34% reported no symptom management [20].
Limitations: Silicolgel is not absorbed, acts locally in the gut, and starts to exert its effects immediately. Efficacy was observed as early as Week 1 with a significant benefit clear after 4 weeks of treatment. The license for silicolgel allows a maximum continuous dose period of 4 weeks; accordingly, this study was limited to 28 days of treatment. However, if symptoms are under control, patients are instructed to take a break of a few days before they begin another course of treatment. Feedback from users who have taken silicolgel for longer than 6 months typically finds they can reduce their dose, or use only if/when they have a flare‐up in symptoms. The safety of silicolgel in long‐term usage has been demonstrated by its excellent safety record on the market in the UK and Europe for over 10 years. However, a long‐term clinical study is warranted to confirm an optimal long‐term IBS dosage strategy.
Thickeners could not be used in placebo as they have a gut effect, thus the viscosity of the placebo was a white, watery solution, whereas silicolgel is a white gel. Both treatments were in opaque, pilfer‐proof bottles and randomization ensured neither patient nor investigator could know which treatment they received. With patients screened for previous use of enterosorbents, and with various other white, watery medications available in Ukraine, it was unlikely the texture of placebo would be seen as unusual, especially given the parallel (non‐crossover) structure of the study. Thus, the likelihood of unblinding bias was considered low. However, it would have been useful to have asked patients after the trial which treatment, active or placebo, they thought they were taking and why. This could have supported blinding.
In retrospect, patients could also have been asked for an overall impression of whether or not their treatment had provided “adequate relief of their IBS.” This would have supported other established measures of efficacy such as IBS SSS.
During the observational period, symptoms gradually returned. At the end of this no‐medication period, it would have been useful to have offered patients treatment with silicolgel to confirm symptoms reduced once again.
5. Conclusion
The findings from the current study, together with other evidence [22, 23, 26, 34], suggest that silica‐based enterosorbents have a favorable safety and tolerability profile and can show clinically meaningful improvements in abdominal pain, stool frequency, and global IBS symptoms.
Silicolgel is a widely available and affordable enterosorbent treatment, providing safe and effective relief of symptoms in patients with IBS‐D and IBS‐M. Based on these findings, its use should be considered more widely for frontline therapy of IBS‐D and IBS‐M. Further clinical research is needed to confirm the optimal long‐term dosage strategy for silicolgel.
6. Escape Medication Usage
Not all assessments are fully reported in this summary. However, during screening, the two treatment groups did not differ in the number of escape medication tablets taken, a confirmation of their initial homogeneity.
From Week 1 of treatment through Week 3 of the observation period with no medication, the number of Mebeverine tablets taken by patients on silicolgel was significantly lower than that in the placebo group. The number of loperamide tablets taken was insufficient for a reliable assessment of the effect each week. However, during the 4‐week treatment period, the total number of loperamide tablets taken in the silicolgel group was significantly lower than that in the placebo group (p = 0.023).
Author Contributions
O. Kuzminska and B. Vitkovska are primary investigators. Yurii Kuvaiskov is responsible for designing and managing the clinical trial and also for assisting with the preparation of the manuscript and statistical analysis (Verum, headquartered in Germany, is a C.R.O. specialist in clinical trials management and operations, operating throughout Europe for over 25 years, with experience working with major multinational pharmaceutical and medical device companies in a wide range of therapeutic areas). Chris G. Hatton is responsible for assisting in the preparation and checking of the manuscript.
Ethics Statement
The clinical study protocol, information for patients with the informed consent of the patient to participate in the clinical study, the investigator's brochure, and other necessary documents were submitted by the sponsor to the Ethics Committee at each site in which the study was conducted. This study was started only after receiving approval to conduct a clinical study and after receiving approval of the clinical study materials by the Committee on Ethics at each of the institutions where the study was conducted. Due to the classification status of the product in Ukraine, this made the trial ineligible for pre‐registration.
Consent
The study followed the principles of the Declaration of Helsinki. All participants provided written informed consent. Participants were not incentivized to take part in this study but, where appropriate, basic travel expenses for Clinic visits were reimbursed.
Conflicts of Interest
The authors declare the following conflict, which may be considered a potential competing interest: Chris G. Hatton is acting as a consultant for FW Medical Ltd. There are no other conflicts of interest.
Supporting information
Appendix S1:
Acknowledgments
FW Medical Ltd. would like to acknowledge the dedication of Verum, the CRO, and the research team in Ukraine and thank them for their excellent work on this study. The authors thank Scientific Writers Ltd. for providing medical writing support, funded by FW Medical Ltd.
Funding: This work was supported by FW Medical Ltd, the owner of silicolgel (silicol®gel) and Delta Medical LLC, the distributor of silicolgel (sold as Filtrum® gastro gel) in Ukraine. FW Medical and Delta Medical had no direct involvement in the study.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Vasant D. H., Paine P. A., Black C. J., et al., “British Society of Gastroenterology Guidelines on the Management of Irritable Bowel Syndrome,” Gut 70, no. 7 (2021): 1214–1240. [DOI] [PubMed] [Google Scholar]
- 2. Lovell R. M. and Ford A. C., “Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta‐Analysis,” Clinical Gastroenterology and Hepatology 10, no. 7 (2012): 712–721. [DOI] [PubMed] [Google Scholar]
- 3. Palsson O. S., Whitehead W., Törnblom H., Sperber A. D., and Simren M., “Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom,” Gastroenterology 158, no. 5 (2020): 1262–1273. [DOI] [PubMed] [Google Scholar]
- 4. Mearin F., Lacy B. E., Chang L., et al., “Bowel Disorders,” Gastroenterology 150, no. 6 (2016): 1393–1407. [DOI] [PubMed] [Google Scholar]
- 5. Sperber A. D., Bangdiwala S. I., Drossman D. A., et al., “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study,” Gastroenterology 160, no. 1 (2021): 99–114.e3. [DOI] [PubMed] [Google Scholar]
- 6. Erdrich S., Hawrelak J. A., Myers S. P., and Harnett J. E., “A Systematic Review of the Association Between Fibromyalgia and Functional Gastrointestinal Disorders,” Therapeutic Advances in Gastroenterology 13 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Zamani M., Alizadeh‐Tabari S., and Zamani V., “Systematic Review With Meta‐Analysis: The Prevalence of Anxiety and Depression in Patients With Irritable Bowel Syndrome,” Alimentary Pharmacology & Therapeutics 50, no. 2 (2019): 132–143. [DOI] [PubMed] [Google Scholar]
- 8. Berman S. M., Naliboff B. D., Suyenobu B., et al., “Reduced Brainstem Inhibition During Anticipated Pelvic Visceral Pain Correlates With Enhanced Brain Response to the Visceral Stimulus in Women With Irritable Bowel Syndrome,” Journal of Neuroscience 28, no. 2 (2008): 349–359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Lovell R. M. and Ford A. C., “Prevalence of Gastro‐Esophageal Reflux‐Type Symptoms in Individuals With Irritable Bowel Syndrome in the Community: A Meta‐Analysis,” American Journal of Gastroenterology 107, no. 12 (2012): 1793–1802. [DOI] [PubMed] [Google Scholar]
- 10. Piacentino D., Cantarini R., Alfonsi M., et al., “Psychopathological Features of Irritable Bowel Syndrome Patients With and Without Functional Dyspepsia: A Cross Sectional Study,” BMC Gastroenterology 11 (2011): 94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Lakhan S. E. and Kirchgessner A., “Gut Inflammation in Chronic Fatigue Syndrome,” Nutrition & Metabolism (London) 7 (2010): 79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Patel P., Bercik P., Morgan D. G., et al., “Irritable Bowel Syndrome Is Significantly Associated With Somatization in 840 Patients, Which May Drive Bloating,” Alimentary Pharmacology & Therapeutics 41, no. 5 (2015): 449–458. [DOI] [PubMed] [Google Scholar]
- 13. Ballou S. and Keefer L., “The Impact of Irritable Bowel Syndrome on Daily Functioning: Characterizing and Understanding Daily Consequences of IBS,” Neurogastroenterology and Motility 29, no. 4 (2017), 10.1111/nmo.12982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Canadian Society of Intestinal Research , “IBS Global Impact Report 2018,” 2017, accessed September 14, 2024, https://badgut.org/ibs‐global‐impact‐report‐2018/.
- 15. Frändemark Å., Törnblom H., Jakobsson S., and Simrén M., “Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem,” American Journal of Gastroenterology 113, no. 10 (2018): 1540–1549. [DOI] [PubMed] [Google Scholar]
- 16. Singh P., Staller K., Barshop K., et al., “Patients With Irritable Bowel Syndrome‐Diarrhea Have Lower Disease‐Specific Quality of Life Than Irritable Bowel Syndrome‐Constipation,” World Journal of Gastroenterology 21, no. 26 (2015): 8103–8109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Flacco M. E., Manzoli L., De Giorgio R., et al., “Costs of Irritable Bowel Syndrome in European Countries With Universal Healthcare Coverage: A Meta‐Analysis,” European Review for Medical and Pharmacological Sciences 23, no. 7 (2019): 2986–3000. [DOI] [PubMed] [Google Scholar]
- 18. Goodoory V. C., Ng C. E., Black C. J., and Ford A. C., “Direct Healthcare Costs of Rome IV or Rome III‐Defined Irritable Bowel Syndrome in the United Kingdom,” Alimentary Pharmacology & Therapeutics 56, no. 1 (2022): 110–120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Black C. J. and Ford A. C., “Best Management of Irritable Bowel Syndrome,” Frontline Gastroenterology 12, no. 4 (2020): 303–315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Canadian Society of Intestinal Research , “Gastrointestinal Society 2016 Survey Results: Irritable Bowel Syndrome (IBS),” accessed September 14, 2024, https://badgut.org/wp‐content/uploads/IBS‐Survey‐Results‐2016.pdf.
- 21. Chang F. Y., Lu C. L., Chen C. Y., and Luo J. C., “Efficacy of Dioctahedral Smectite in Treating Patients of Diarrhea‐Predominant Irritable Bowel Syndrome,” Journal of Gastroenterology and Hepatology 22, no. 12 (2007): 2266–2272. [DOI] [PubMed] [Google Scholar]
- 22. Tack J. F., P. B. Miner, Jr. , Fischer L., and Harris M. S., “Randomized Clinical Trial: The Safety and Efficacy of AST‐120 in Non‐Constipating Irritable Bowel Syndrome—A Double‐Blind, Placebo‐Controlled Study,” Alimentary Pharmacology & Therapeutics 34, no. 8 (2011): 868–877. [DOI] [PubMed] [Google Scholar]
- 23. Howell C. A., Kemppinen A., Allgar V., et al., “Double‐Blinded Randomized Placebo‐Controlled Trial of Enterosgel (Polymethylsiloxane Polyhydrate) for the Treatment of IBS With Diarrhea (IBS‐D),” Gut 71, no. 12 (2022): 2430–2438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Park G. D., Spector R., Goldberg M. J., and Johnson G. F., “Expanded Role of Charcoal Therapy in the Poisoned and Overdosed Patient,” Archives of Internal Medicine 146, no. 5 (1986): 969–973. [PubMed] [Google Scholar]
- 25. Guss D. A., “Emergency Medicine: Activated Charcoal‐The First‐Line Agent in Cases of Overdose,” Western Journal of Medicine 151, no. 1 (1989): 63. [PMC free article] [PubMed] [Google Scholar]
- 26. Uehleke B., Ortiz M., and Stange R., “Silicea Gastrointestinal Gel Improves Gastrointestinal Disorders: A Non‐Controlled, Pilot Clinical Study,” Gastroenterology Research and Practice 2012 (2012): 750750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Swinyard E. and Pathak M., “Surface Acting Drugs,” in The Pharmacological Basis of Therapeutics, 6th ed. (Macmillan, 1980). [Google Scholar]
- 28. Kachel G. and Ruppin H., “Akute Diarroe: Diagnostik Und Therapie,” Deutsche Apotheker‐Zeitung 122, no. 31 (1982): 1604–1610. [Google Scholar]
- 29. Rateau J. G., Morgant G., Droy‐Priot M. T., and Parier J. L., “A Histological, Enzymatic and Water‐Electrolyte Study of the Action of Smectite, a Mucoprotective Clay, on Experimental Infectious Diarrhea in the Rabbit,” Current Medical Research and Opinion 8, no. 4 (1982): 233–241. [DOI] [PubMed] [Google Scholar]
- 30. Wagner S., “Kolloidales Siliciumdioxid Bei Colitis Ulcerosa Und Morbus Crohn ‐ Eine Therapeutische Alternative Zur Herkömmlichen Behandlung,” Die Therapiewoche 32 (1982): 6185–6190. [Google Scholar]
- 31. Howell C. A., Mikhalovsky S. V., Markaryan E. N., and Khovanov A. V., “Investigation of the Adsorption Capacity of the Enterosorbent Enterosgel for a Range of Bacterial Toxins, Bile Acids and Pharmaceutical Drugs,” Scientific Reports 9, no. 1 (2019): 5629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Howell C. A., Markaryan E., Allgar V., et al., “Enterosgel for the Treatment of Adults With Acute Diarrhea in a Primary Care Setting: A Randomized Controlled Trial,” BMJ Open Gastroenterology 6, no. 1 (2019): e000287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. FW Medical Ltd , “Silicolgel for Gastrointestinal Disorders,” accessed September 14, 2024, https://www.silicol.co.uk/.
- 34. Crawford G., Taylor R., Young D., and Hatton C. G., “Efficacy of the Enterosorbent SilicolGel in Adults With Irritable Bowel Syndrome Subtypes IBS‐D or Mixed: Observational Open‐Label Study,” Gastroenterology Research and Practice 2023 (2023): 3432763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Francis C. Y., Morris J., and Whorwell P. J., “The Irritable Bowel Severity Scoring System: A Simple Method of Monitoring Irritable Bowel Syndrome and Its Progress,” Alimentary Pharmacology & Therapeutics 11, no. 2 (1997): 395–402. [DOI] [PubMed] [Google Scholar]
- 36. European Medicines Agency , “Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome—Scientific Guideline,” 2014, accessed September 14, 2024, https://www.ema.europa.eu/en/evaluation‐medicinal‐products‐treatment‐irritable‐bowel‐syndrome‐scientific‐guideline.
- 37. The European Parliament and the Council of the European Union , “Medical Devices Regulation EU2017\745 (Medical Devices),” accessed September 14, 2024, https://eur‐lex.europa.eu/legal‐content/EN/TXT/PDF/?uri=CELEX:32017R0745.
- 38. Lembo A., Kelley J. M., Nee J., et al., “Open‐Label Placebo vs Double‐Blind Placebo for Irritable Bowel Syndrome: A Randomized Clinical Trial,” Pain 162, no. 9 (2021): 2428–2435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Rangan V., Ballou S., Shin A., Camilleri M., Beth Israel Deaconess Medical Center GI Motility Working Group , and Lembo A., “Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey,” Gastroenterology 158, no. 3 (2020): 786–788.e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Dionne J., Ford A. C., Yuan Y., et al., “A Systematic Review and Meta‐Analysis Evaluating the Efficacy of a Gluten‐Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome,” American Journal of Gastroenterology 113, no. 9 (2018): 1290–1300. [DOI] [PubMed] [Google Scholar]
- 41. Ford A. C., Moayyedi P., Chey W. D., et al., “American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome,” American Journal of Gastroenterology 113, no. Suppl 2 (2018): 1–18. [DOI] [PubMed] [Google Scholar]
- 42. Gorard D. A., Libby G. W., and Farthing M. J., “Influence of Antidepressants on Whole Gut and Orocaecal Transit Times in Health and Irritable Bowel Syndrome,” Alimentary Pharmacology & Therapeutics 8, no. 2 (1994): 159–166. [DOI] [PubMed] [Google Scholar]
- 43. Min Y. W. and Rhee P. L., “The Clinical Potential of Ramosetron in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS‐D),” Therapeutic Advances in Gastroenterology 8, no. 3 (2015): 136–142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Black C. J., Burr N. E., Camilleri M., et al., “Efficacy of Pharmacological Therapies in Patients With IBS With Diarrhea or Mixed Stool Pattern: Systematic Review and Network Meta‐Analysis,” Gut 69, no. 1 (2020): 74–82. [DOI] [PubMed] [Google Scholar]
- 45. Garsed K., Chernova J., Hastings M., et al., “A Randomized Trial of Ondansetron for the Treatment of Irritable Bowel Syndrome With Diarrhea,” Gut 63, no. 10 (2014): 1617–1625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Lacy B. E., Chey W. D., Cash B. D., Lembo A. J., Dove L. S., and Covington P. S., “Eluxadoline Efficacy in IBS‐D Patients Who Report Prior Loperamide Use,” American Journal of Gastroenterology 112, no. 6 (2017): 924–932. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Appendix S1:
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
